Atorvastatin

Overview

Atorvastatin is a statin-class lipid-lowering drug used primarily to reduce low-density lipoprotein cholesterol and cardiovascular risk. Like other statins, it acts by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby lowering hepatic cholesterol production and increasing LDL receptor expression. Beyond its established role in dyslipidemia and atherosclerotic cardiovascular disease prevention, atorvastatin is also widely studied for pleiotropic effects related to inflammation, oxidative stress, endothelial function, and vascular remodeling.

In recent biomedical research, atorvastatin has been investigated not only as a cardiovascular therapy but also as a modulator of calcification, macrophage polarization, and cancer cell biology. The studies provided here examine its effects in plaque-relevant vascular and stromal cells, in atherosclerosis models, in spinal cord injury target prediction, and in colorectal cancer combination strategies with sorafenib or SREBP2 inhibitors. These contexts reflect interest in atorvastatin as a biologically active small molecule with potential effects extending beyond cholesterol lowering.

Focus of Latest Publications

Recent publications have examined atorvastatin in several experimental and translational settings, most often as a comparator or combination partner rather than as a stand-alone intervention. In colorectal cancer models, atorvastatin was studied with sorafenib to test whether the combination could trigger mixed cell death through apoptosis and ferroptosis. The combination showed synergy in multiple colon cancer cell lines, with a combination index below 1 and a dose reduction index above 1, and it increased markers associated with oxidative stress and membrane damage while reducing antioxidant levels. The same study also reported anti-metastatic effects in migration, invasion, and wound-healing assays, along with about 80% tumor growth inhibition in vivo, although systemic, organ, and hemolytic toxicity were also observed.

Other cancer-focused work evaluated atorvastatin alongside SREBP2 inhibitors in colorectal cancer cells cultured in both two-dimensional and three-dimensional systems. This study was designed around the idea that SREBP2 contributes to statin resistance and that inhibiting it may enhance statin cytotoxicity, but the abstract does not provide the outcome data. A separate publication on anthracycline-based chemotherapy investigated whether atorvastatin could protect against reductions in left ventricular global longitudinal strain and global circumferential strain, but the abstract likewise does not report the results.

Beyond oncology, atorvastatin has been explored in cardiovascular and calcification-related models. In a study of plaque-relevant stromal and vascular cells, atorvastatin was tested in monolayer cultures and in a tissue-engineered 3D plaque cap model. The effects were cell type-specific: atorvastatin inhibited calcification in mesenchymal stromal cells, induced calcification in smooth muscle-like cells derived from them, and reduced calcification in human vena saphena cells in 2D while showing no visible effect in 3D. These findings suggest that atorvastatin’s influence on calcification depends on cellular context and model system.

Atorvastatin has also appeared in pharmacological safety and repurposing contexts. A target trial emulation compared rosuvastatin versus atorvastatin for short-term effects on corrected QT interval, aiming to reproduce randomized trial findings using electronic health record data, but the abstract does not state the outcome. In spinal cord injury research, atorvastatin was identified through in silico drug prediction as a potential modulator of macrophage polarization, alongside dexamethasone, in a gene-based analysis centered on Soat1, Comt, and Myo1f. In addition, a natural products study used atorvastatin as a positive control in OA-induced HepG2 cells and found that several biphenyl derivatives from Garcinia nujiangensis showed stronger lipid-lowering effects than atorvastatin.

Key Publications

NEWJun Bioactive biphenyl derivatives from Garcinia nujiangensis and structural revision. (Fitoterapia, 2026, PMID 42297079): "Additionally, six compounds (1, 2, 6, 7, 9, and 10) exhibited stronger lipid-lowering effects than the positive control (atorvastatin) in OA-induced HepG2 cells."
May Exploring Synergistic Potential of Sorafenib and Atorvastatin to Launch Apoptosis and Ferroptosis-driven Mixed Cell Death Mechanism in Colorectal Cancer. (AAPS PharmSciTech, 2026, PMID 42204072): "The present investigation explores the combined therapy of Sorafenib (SOR) and Atorvastatin (ATST) to induce a dual cell death mechanism, specifically ferroptosis and classic apoptosis, in colon cancer cells."
May Short-term effect of rosuvastatin versus atorvastatin on the corrected QT interval: a target trial emulation. (European journal of clinical pharmacology, 2026, PMID 42104119): "To estimate the short-term effect of rosuvastatin versus atorvastatin on the corrected QT interval (QTc) by emulating a published randomized controlled trial (RCT) using electronic health record (EHR) data,"
May Screening macrophage polarization genes in spinal cord injury as therapeutic targets. (PloS one, 2026, PMID 42081466): "In silico drug prediction identified 37 small molecules, including dexamethasone and atorvastatin, as potential modulators of macrophage polarization in SCI."
May Evaluation of Combined Treatment With Atorvastatin and SREBP2 Inhibitors Against Colorectal Cancer Cells Under Two-dimensional and Three-dimensional Culture Models. (Anticancer research, 2026, PMID 42049373): "In this study, we evaluated the cytotoxicity induced by combined treatment with atorvastatin and SREBP2 inhibitors in 2D and 3D cultured colorectal cancer (CRC) cells."
May Differential effects of atorvastatin on calcification in stromal and vascular cells within monolayer and 3D plaque cap models. (Biochemical and biophysical research communications, 2026, PMID 41916005): "To address this gap, we investigated the impact of atorvastatin on calcification across multiple plaque-relevant cell types using both monolayer cultures and a tissue-engineered 3D plaque model."
Mar Atorvastatin and left ventricular strain during anthracycline-based chemotherapy. (International journal of cardiology, 2026, PMID 41875954): "Whether atorvastatin protects against anthracycline-induced reductions in GLS and GCS is unknown."